Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ipilimumab/nivolumab

Various toxicities: 2 case reports

    • 13 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Mencel J, et al. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma. Asia-Pacific Journal of Clinical Oncology 15: 383-386, No. 6, Dec 2019. Available from: URL: http://doi.org/10.1111/ajco.13233

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Ipilimumab/nivolumab. Reactions Weekly 1790, 141 (2020). https://doi.org/10.1007/s40278-020-74760-6

    Download citation